Cystic Fibrosis IVF Screening in Thailand: PGT-M Testing & Considerations
Opening: Real consultation scenario
A 28-year-old woman diagnosed with cystic fibrosis (CF) came to the clinic. Her husband was confirmed as a carrier through genetic testing. She asked: "If I go to Thailand for IVF, can this disease be screened out?" The question is straightforward, and the answer is clear: yes, but with strict conditions and procedures. Below, I break down from a clinical perspective which cases are suitable, how it is specifically done, and where problems are most likely to occur.
Core Answer: Cystic fibrosis can be screened in Thailand
Some reproductive centers in Thailand with third-generation IVF (PGT) qualifications offer PGT-M (Preimplantation Genetic Testing for Monogenic Diseases) services. For cystic fibrosis caused by CFTR gene mutations, the laboratory can perform genetic testing on trophectoderm cells of the embryo to select embryos without pathogenic mutations for transfer. However, the prerequisite is: the specific pathogenic mutation site must be clearly identified, and family verification and probe preparation must be completed. It cannot be done directly in every situation.
Why is specialized screening necessary? Disease genetic background
Cystic fibrosis is an autosomal recessive genetic disorder. If both partners are carriers (each carrying one mutation), there is a 25% chance of having an affected child in each pregnancy. If one partner is diagnosed with CF (double mutation) and the other is a carrier, the offspring have a 50% chance of developing the disease. PGT-M can accurately identify whether an embryo carries double or single mutations, allowing selection of embryos that are only carriers or mutation-free for transfer.
Thailand has a relatively relaxed legal environment for genetic disease screening, allowing embryo genetic testing for known pathogenic sites. However, probe design capabilities and verification standards vary among laboratories, directly affecting screening accuracy.
Reproductive Doctor's Perspective: Which patients are suitable? Which are not?
Suitable candidates:
- One or both partners have a confirmed diagnosis of cystic fibrosis or are confirmed as carriers of pathogenic mutations through genetic testing
- Must provide a genetic report from a domestic top-tier hospital or authoritative institution, specifying the mutation site (e.g., ΔF508, G551D, etc.)
- The female has adequate ovarian reserve (AMH ≥ 1.0 ng/mL, antral follicle count ≥ 6) to obtain sufficient eggs for embryo biopsy
- Both parties have signed informed consent, understanding the risks of misdiagnosis or mosaicism associated with PGT-M
Unsuitable candidates:
- Family verification not completed; only known as a carrier without identifying the specific mutation site
- Female ovarian failure (AMH < 0.5 or FSH > 15), potentially unable to obtain embryos suitable for biopsy
- Other unassessed genetic factors (e.g., chromosomal translocations) requiring karyotype analysis first
- Unacceptable risk expectations regarding Thailand's embryo genetic testing regulations or procedures
Easily overlooked detail: Probe preparation and family verification
Many patients assume they can directly undergo egg retrieval and immediate genetic screening upon arrival in Thailand. In practice, probe preparation requires obtaining DNA samples from both partners (and sometimes the proband or affected child) to construct specific detection probes for the family's mutation site. This process typically takes 2–4 weeks and must be completed before starting the cycle. If one partner's genetic report is incomplete, or family members cannot provide blood samples, probe preparation may fail, making PGT-M impossible.
Additionally, some laboratories in Thailand only accept CNV or SNP reports from Chinese top-tier hospitals and have high requirements for raw data from gene chips or high-throughput sequencing. It is recommended to send the domestic genetic report to the Thai laboratory for pre-evaluation to confirm feasibility before deciding to travel to Thailand.
Complete process for cystic fibrosis screening in Thailand
Phase 1: Domestic preparation (1–2 months)
- Genetic counseling: A geneticist evaluates family history, confirms cystic fibrosis diagnosis and inheritance pattern
- Genetic testing: Both partners undergo CFTR whole-exome sequencing or known hotspot mutation testing to identify mutation sites (e.g., ΔF508, G542X, etc.)
- Family verification: If an affected child or proband exists, their DNA sample must also be submitted for probe design
- Basic fertility assessment: AMH, FSH, LH, antral follicle count, semen analysis, infectious disease screening (HIV, hepatitis B, syphilis, etc.)
Phase 2: Liaison with Thai laboratory (4 weeks before cycle start)
- Send domestic genetic reports, blood samples, or DNA samples to the collaborating Thai laboratory
- The Thai laboratory performs probe design and validation, issuing a probe feasibility report
- Simultaneously, complete female uterine cavity examination (hysteroscopy or sonohysterography) to rule out endometrial pathology
Phase 3: Cycle stimulation and egg retrieval (approximately 2 weeks)
- On day 2 of menstruation, register at the Thai hospital and sign PGT-M informed consent
- Ovarian stimulation protocol (commonly antagonist or GnRH agonist), individualized based on age and AMH
- Egg retrieval surgery (painless), IVF (ICSI)
Phase 4: Embryo culture and biopsy (5–7 days)
- Embryos cultured to blastocyst stage (D5/D6), biopsy of 3–5 trophectoderm cells
- Embryos frozen after biopsy (vitrification), awaiting test results
Phase 5: PGT-M testing (2–4 weeks)
- Thai laboratory performs whole genome amplification, designs primers for CFTR mutation sites, and conducts Sanger sequencing or NGS testing
- Simultaneously, chromosomal aneuploidy screening (PGT-A) is recommended to avoid transferring embryos with chromosomal abnormalities
- Issues embryo genetic testing report, indicating mutation status for each embryo: normal/carrier/affected
Phase 6: Frozen embryo transfer (1 month later)
- Select 1–2 blastocysts without pathogenic mutations for transfer on cycle days 17–21
- Luteal phase support after transfer, blood test for HCG 12 days post-transfer to confirm pregnancy
Timeline: Approximately 4–6 months from preparation to transfer
| Phase | Time required | Shortening options |
|---|---|---|
| Domestic genetic counseling + testing + family verification | 4–8 weeks | Choose a center that can issue reports for both parties simultaneously |
| Probe preparation and laboratory validation | 2–4 weeks | Share genetic information with Thai side in advance domestically |
| Cycle stimulation + egg retrieval | Approximately 2 weeks | Start cycle during follicular phase, no waiting |
| Embryo culture + biopsy + PGT-M testing | 3–5 weeks | Some laboratories can accelerate to 2 weeks |
| Frozen embryo transfer + pregnancy test | 4–6 weeks | Endometrial preparation cycle can be flexibly scheduled |
If the female has low AMH or is of advanced age, multiple egg retrieval cycles may be needed to accumulate embryos, potentially extending the total timeline to 8–12 months.
Frequently asked questions summary
Q1: Can all reproductive centers in Thailand perform PGT-M for cystic fibrosis?
No. Only centers with independent genetic laboratories or partnerships with certified overseas genetic testing companies offer this service. It is recommended to choose institutions with over 200 PGT cycles annually and more than 5 years of experience in monogenic disease testing.
Q2: How accurate is PGT-M?
With correct probe design and sufficient embryo biopsy cells, the accuracy of monogenic disease testing is approximately 97%–99%. There is a 1%–3% risk of misdiagnosis (mosaicism, amplification failure, or sample contamination). Therefore, prenatal diagnosis (chorionic villus sampling or amniocentesis) is recommended after transfer for confirmation.
Q3: Can I skip PGT-M and directly undergo prenatal diagnosis?
Yes. However, if prenatal diagnosis detects an affected fetus, termination of pregnancy is required. For women with multiple failed pregnancies or advanced age, PGT-M significantly reduces the probability of transferring affected embryos and decreases pregnancy loss due to genetic causes.
Q4: What documents do cystic fibrosis carriers need to prepare for Thailand?
Passport (valid for at least 1 year recommended), marriage certificate, and ID documents for both parties. Some hospitals may require a male semen analysis report and female hysterosalpingography (if needed) issued by domestic hospitals.
Q5: What is the approximate cost of PGT-M in Thailand?
Stimulation + egg retrieval + embryo culture + PGT-M (monogenic + aneuploidy screening) totals approximately 120,000–200,000 Thai Baht (about RMB 24,000–40,000), excluding medication, accommodation, and transportation. Prices vary significantly between centers; confirm whether probe preparation fees are included.
Practitioner observations: Most common pitfalls
We have encountered many families with insufficient preparation before traveling to Thailand, leading to cycle delays or failures. The main issues are:
- Incomplete genetic reports: Domestic testing only performed "whole-exome sequencing" without specifying the mutation site name (e.g., c.1521_1523delCTT), making it impossible for Thai laboratories to design probes directly. Detailed reports including HGVS nomenclature are required.
- Neglecting male genetic assessment: If the male only had a normal semen analysis without genetic screening, and the female is a carrier, the possibility of the male being a CFTR carrier may be missed. It is recommended that both partners complete full-spectrum CFTR testing.
- Expected embryo count: During PGT-M, biopsy and freezing can cause some embryos to degenerate. For women over 38, an average of 4 blastocysts may yield only 1 normal embryo. If few eggs are retrieved, there may be no transferable embryos.
Risk warnings:
1. PGT-M cannot 100% rule out embryos carrying pathogenic mutations; there is a very low probability of amplification failure or maternal contamination. After pregnancy, prenatal diagnosis (amniocentesis after 16 weeks of gestation) must be performed to confirm the true fetal genotype.
2. Probe validation timelines and quality control standards vary among Thai laboratories. Choose laboratories with JCI certification or ISO 15189 accreditation.
3. No genetic test can change the genetic composition of an embryo; it only screens. If all embryos carry mutations or no embryos are available for transfer, reassessment of whether to accept donor eggs or embryos is necessary.
